You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)擬議成立基金從事合成生物學、創新藥物及生物技術領域高增長企業投資

格隆匯8月12日丨華潤醫藥(03320.HK)公告,華潤醫藥(汕頭)、華潤雙鶴、雙鶴(北京)、華潤醫藥投資(各自爲公司附屬公司)與漢威華酉汕頭及其他有意合夥人就成立預期規模爲人民幣5億元基金進行協商。基金預期主要從事合成生物學、創新藥物及生物技術領域的高增長企業投資。

集團擬承諾出資總額預期爲不高於人民幣1.23億元,約佔基金承諾出資總額的24.6%。預期基金於成立後將不會入賬爲公司附屬公司。預期深圳華潤資本將獲委託爲基金基金管理人。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account